Cytori Therapeutics News

David Gardner called it. Hea s up 1,334%! See what Davida s recommending that you buy NEXT.

Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, stem-cell technology specialist Cytori Therapeutics has earned a respected four-star ranking .

Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.

On 11/16/09, Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.

Nov. 16 -- Mark Saad, chief financial officer of Cytori Therapeutics, talks with Bloomberg's Pimm Fox about the outlook for his company and regenerative medicine.

Noble Financial Stephen Dunn - Jesup Lamont Neil Gagnon - Gagnon Securities Bart Blout - Sawtooth Capital Presentation Operator Good day ladies and gentlemen.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the... CHICAGO-- --Zacks.com announces the list of stocks featured in the Analyst Blog.

Cytori Therapeutics sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science that demonstrated the safety and feasibility of using a patient's own adipose-derived stem and regenerative cells ) processed by ...

Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks.

Cytori Therapeutics reported results from their preclinical study on the use of uncultured adipose-derived regenerative cells in the treatment of critical periodontal defects in a rat model.

Cytori Therapeutics will present and provide a webcast of its corporate presentation at the Rodman & Renshaw Annual Global Healthcare Investment Conference on Thursday, September 10 at 10:50 AM Eastern Time.

Cytori Therapeutics reports financial results for the quarter ended June 30, 2009.

Cytori Therapeutics reports financial results for the quarter ended June 30, 2009.

Aug 10, 2009 - Cytori Therapeutics reports financial results for the quarter ended June 30, 2009.

Cytori Therapeutics Inc. will webcast its second quarter financial results and management discussion on Monday, August 10, 2009 at 10:30 AM Eastern Time.

Main Category: Medical Devices / Diagnostics Also Included In: Cosmetic Medicine / Plastic Surgery Cytori Therapeutics was informed by the U.S. Food and Drug Administration that the Celution 700 System will be regulated as a medical device under the Federal Food, Drug, and Cosmetic Act.

Cytori Therapeutics, Inc. recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the CelutionA System for the treatment of bone related disorders.

Investment opinion and research company InvestorSoup.com announces the availability of free, detailed stock alerts on active stocks in today's news.

Cytori Therapeutics entered into an equity agreement with Seaside 88, LP . Under the terms of the agreement, Seaside has committed to purchase up to 7.15 million Cytori common shares, in a series of closings every two weeks in the amount of 275,000 shares each for a total of up to 26 purchases.